Colistin-sulbactam combination significantly improves microbiological eradication and clinical cure in CRAB pneumonia.
Background
Carbapenem-resistant Acinetobacter baumannii (CRAB) pneumonia, including hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP), presents a critical challenge due to limited effective treatment options and high mortality. Optimal combination therapy remains controversial, with regimens like colistin-sulbactam and colistin-tigecycline frequently used but lacking clear comparative efficacy data. This study addresses the urgent need for evidence-based guidance on superior antimicrobial strategies for severe CRAB infections, particularly concerning microbiological eradication and clinical outcomes.
Study Design
A single-center, retrospective cohort study analyzed adult patients with culture-confirmed CRAB HAP/VAP from 2019-2024. Patients received either colistin-sulbactam (Group A) or colistin-tigecycline (Group B) for at least 72 hours. Propensity score matching (PSM) created 42 matched pairs (n=84), balancing baseline covariates like APACHE II scores and renal function. The primary endpoint was microbiological eradication at Day 7, with secondary endpoints including 28-day all-cause mortality, clinical cure, and adverse events.
Results
The colistin-sulbactam group demonstrated significantly superior microbiological eradication rates at Day 7 compared to the colistin-tigecycline group, achieving 66.7% versus 40.5% respectively (P = 0.013). This benefit was particularly evident in patients with extensively drug-resistant (XDR) strains and those with multisite colonization, where the odds ratio for eradication was 4.75 (95% CI 1.58-14.26).
Key Findings
- Colistin-sulbactam achieved 66.7% microbiological eradication at
Day 7vs. 40.5% for colistin-tigecycline (P = 0.013). - Clinical cure rates were higher with colistin-sulbactam (59.5% vs. 35.7%; P = 0.029).
- The benefit was pronounced in XDR strains and multisite colonization (OR 4.75; 95% CI 1.58-14.26).
- No significant difference in 28-day all-cause mortality (31.0% vs. 38.1%; P = 0.490).
- Colistin-sulbactam offers a favorable efficacy and safety profile for severe CRAB infections.
Why It Matters
This study provides crucial evidence supporting colistin combined with high-dose sulbactam as a preferred therapeutic strategy for severe CRAB HAP/VAP, especially in cases involving XDR strains or high bacterial burden. Clinicians now have stronger data to guide antibiotic selection, potentially improving patient outcomes by achieving higher microbiological clearance and clinical cure rates. While both regimens are currently used, this research clarifies the superior efficacy of the sulbactam-based approach, suggesting a shift in standard practice. The findings underscore the importance of optimizing combination therapies to combat escalating antimicrobial resistance, offering a more effective protocol for a challenging infection.
colistin
sulbactam
tigecycline
crab
pneumonia
hap